{"id":2307,"date":"2017-09-28T19:20:03","date_gmt":"2017-09-28T19:20:03","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/phararb\/"},"modified":"2025-05-13T20:25:29","modified_gmt":"2025-05-13T20:25:29","slug":"phararb","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/phararb\/","title":{"rendered":"Eficacia y Seguridad de los Antagonistas de los Receptores de Angiotensina"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p><\/p>\n<div>La aparici\u00f3n de antagonistas de los receptores de angiotensina (ARA II) entre las opciones terap\u00e9uticas en el tratamiento de las enfermedades cardiovasculares (ECV) fue un nuevo hito en la historia del tratamiento de la hipertensi\u00f3n. Adem\u00e1s, ampli\u00f3 el abanico de posibilidades de terapia personalizada, especialmente para pacientes que no pueden tolerar el uso de inhibidores de la enzima convertidora de la angiotensina (IECA).<\/div>\n<p><!--more--><\/p>\n<p style=\"font-weight: 400;\"><strong>Caracter\u00edsticas farmacol\u00f3gicas de los\u00a0Antagonistas de los Receptores de Angiotensina II (ARA II)<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr style=\"height: 96px;\">\n<td style=\"height: 96px; width: 19.0068%;\"><strong>ARA II<\/strong><\/td>\n<td style=\"height: 96px; text-align: center; width: 13.5274%;\"><strong>Vida media (h)\u00a0<\/strong><\/td>\n<td style=\"height: 96px; text-align: center; width: 8.56164%;\"><strong>Tmax (h)<\/strong><\/td>\n<td style=\"text-align: center; height: 96px; width: 19.1781%;\"><strong>Bio-disponibilidad<\/strong><\/td>\n<td style=\"text-align: center; height: 96px; width: 21.2329%;\"><strong>V\u00eda de eliminaci\u00f3n:<\/strong><br \/>\n<strong>renal(R), biliar\/fecal(B)<\/strong><\/td>\n<td style=\"text-align: center; height: 96px; width: 18.4932%;\"><strong>Interacci\u00f3n con alimentos<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Losart\u00e1n*<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a02<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a01\u20131.5<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a033%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">35% R; 60% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0Si<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Candesart\u00e1n cilexetil<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a09<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a02-5<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a042%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">33% R; 67% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0No<\/td>\n<\/tr>\n<tr style=\"height: 24px;\">\n<td style=\"height: 24px; width: 19.0068%;\">Eprosart\u00e1n<\/td>\n<td style=\"text-align: center; height: 24px; width: 13.5274%;\">\u00a05\u20139<\/td>\n<td style=\"text-align: center; height: 24px; width: 8.56164%;\">\u00a01\u20133<\/td>\n<td style=\"text-align: center; height: 24px; width: 19.1781%;\">\u00a063%<\/td>\n<td style=\"text-align: center; height: 24px; width: 21.2329%;\">7% R; 90% B<\/td>\n<td style=\"text-align: center; height: 24px; width: 18.4932%;\">\u00a0Si<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Irbesart\u00e1n<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a011\u201315<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a01.3\u20133<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a060\u201380%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">20% R; 80% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0No<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Telmisart\u00e1n<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a024<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a00.5\u20131<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a043%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">&lt;1% R; &gt;97% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0No<\/td>\n<\/tr>\n<tr style=\"height: 24px;\">\n<td style=\"height: 24px; width: 19.0068%;\">Valsart\u00e1n<\/td>\n<td style=\"text-align: center; height: 24px; width: 13.5274%;\">\u00a06<\/td>\n<td style=\"text-align: center; height: 24px; width: 8.56164%;\">\u00a02\u20134<\/td>\n<td style=\"text-align: center; height: 24px; width: 19.1781%;\">\u00a023%<\/td>\n<td style=\"text-align: center; height: 24px; width: 21.2329%;\">13% R; 83% B<\/td>\n<td style=\"text-align: center; height: 24px; width: 18.4932%;\">\u00a0Si<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Olmesart\u00e1n medoxomil<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a012\u201314<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a01.7\u20132.5<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a026%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">35\u201350%R; 50\u201365% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0No<\/td>\n<\/tr>\n<tr style=\"height: 48px;\">\n<td style=\"height: 48px; width: 19.0068%;\">Azilsart\u00e1n medoxomil<\/td>\n<td style=\"text-align: center; height: 48px; width: 13.5274%;\">\u00a012<\/td>\n<td style=\"text-align: center; height: 48px; width: 8.56164%;\">\u00a01.5\u20133<\/td>\n<td style=\"text-align: center; height: 48px; width: 19.1781%;\">\u00a060%<\/td>\n<td style=\"text-align: center; height: 48px; width: 21.2329%;\">42% orina; 55% B<\/td>\n<td style=\"text-align: center; height: 48px; width: 18.4932%;\">\u00a0No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>* Losart\u00e1n se convierte en EXP-3174 con vida media terminal de 6-9 horas y Tmax de 4-6 horas.<\/p>\n<p><strong>Dosis para hipertensi\u00f3n y otras indicaciones de los antagonistas de los receptores de angiotensina II<\/strong><\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr>\n<td><strong>ARA II<\/strong><\/td>\n<td><strong>Dosis inicial (mg\/d\u00eda)<\/strong><\/td>\n<td><strong>Dosis m\u00e1xima (mg\/d\u00eda)<\/strong><\/td>\n<td><strong>Intervalo de dosis<\/strong><\/td>\n<td><strong>Otras indicaciones aprobadas fuera de la hipertensi\u00f3n<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Losart\u00e1n<\/td>\n<td>\u00a050<\/td>\n<td>\u00a0100<\/td>\n<td>Una vez al d\u00eda o dos veces al d\u00eda<\/td>\n<td>Nefropat\u00eda diab\u00e9tica cuando la creatinina s\u00e9rica est\u00e1 aumentada y la proteinuria presente en pacientes con hipertensi\u00f3n y diabetes tipo 2; Reducci\u00f3n del ictus en pacientes con hipertensi\u00f3n e hipertrofia ventricular izquierda (solo no raza negra)<\/td>\n<\/tr>\n<tr>\n<td>Candesart\u00e1n cilexetil<\/td>\n<td>\u00a016<\/td>\n<td>\u00a032<\/td>\n<td>Una vez al d\u00eda o dos veces al d\u00eda<\/td>\n<td>Tratamiento de la insuficiencia card\u00edaca (Clases NYHA II-IV)<\/td>\n<\/tr>\n<tr>\n<td>Eprosart\u00e1n<\/td>\n<td>\u00a0600<\/td>\n<td>\u00a0800<\/td>\n<td>Una vez al d\u00eda o dos veces al d\u00eda<\/td>\n<td>Ninguna<\/td>\n<\/tr>\n<tr>\n<td>Irbesart\u00e1n<\/td>\n<td>\u00a0150<\/td>\n<td>\u00a0300<\/td>\n<td>Una vez al d\u00eda<\/td>\n<td>Nefropat\u00eda diab\u00e9tica cuando aumenta la creatinina s\u00e9rica y se presenta proteinuria en pacientes con hipertensi\u00f3n y diabetes tipo 2<\/td>\n<\/tr>\n<tr>\n<td>Telmisart\u00e1n<\/td>\n<td>\u00a040<\/td>\n<td>\u00a080<\/td>\n<td>Una vez al d\u00eda<\/td>\n<td>Reducci\u00f3n del riesgo cardiovascular en pacientes con efectos colaterales a los IECA<\/td>\n<\/tr>\n<tr>\n<td>Valsart\u00e1n<\/td>\n<td>\u00a080 o 160<\/td>\n<td>\u00a0320<\/td>\n<td>Una vez al d\u00eda<\/td>\n<td>Tratamiento de la insuficiencia card\u00edaca (Clases NYHA II-IV); Reducci\u00f3n de la mortalidad CV en pacientes cl\u00ednicamente estables con insuficiencia\u00a0o disfunci\u00f3n ventricular izquierda despu\u00e9s del infarto de miocardio.<\/td>\n<\/tr>\n<tr>\n<td>Olmesart\u00e1n medoxomil<\/td>\n<td>\u00a020<\/td>\n<td>\u00a040<\/td>\n<td>Una vez al d\u00eda<\/td>\n<td>Ninguna<\/td>\n<\/tr>\n<tr>\n<td>Azilsart\u00e1n medoxomil<\/td>\n<td>\u00a040 o 80<\/td>\n<td>\u00a080<\/td>\n<td>Una vez al d\u00eda<\/td>\n<td>Ninguna<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: 400;\"><strong>Bibliograf\u00eda:<\/strong><\/p>\n<ol>\n<li>Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.\u00a0Drug Saf. 2015 Jan;38(1):33-54. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25416320\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.\u00a0Eur Heart J. 2014 Jul;35(26):1732-42. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23966312\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>D\u00e9zsi CA. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? Am J Cardiovasc Drugs. 2016 Aug;16(4):255-66. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26940560\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p style=\"font-weight: 400;\">Creado Sep 28, 2017.<\/p>\n<p><\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>La aparici\u00f3n de antagonistas de los receptores de angiotensina (ARA II) entre las opciones terap\u00e9uticas en el tratamiento de las enfermedades cardiovasculares (ECV) fue un nuevo hito en la historia del tratamiento de la hipertensi\u00f3n. Adem\u00e1s, ampli\u00f3 el abanico de posibilidades de terapia personalizada, especialmente para pacientes que no pueden tolerar el uso de inhibidores [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[594],"tags":[608,607,606,605,604,603,602,601,600,561,562,599,564,598,597,596,595,609],"class_list":["post-2307","post","type-post","status-publish","format-standard","hentry","category-pharmacology","tag-acei","tag-aceis","tag-angiotensin","tag-angiotensina","tag-antagonistas","tag-ara","tag-arb","tag-arbs","tag-blockers","tag-comparativa","tag-comparative","tag-efficacy","tag-eficacia","tag-ieca","tag-receptor","tag-receptores","tag-safety","tag-seguridad"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=2307"}],"version-history":[{"count":3,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2307\/revisions"}],"predecessor-version":[{"id":8738,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2307\/revisions\/8738"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=2307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=2307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=2307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}